Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Share-based Compensation (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Share-based Compensation for 5 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 50.8% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.0 million through Dec 2025, down 31.11% year-over-year, with the annual reading at $9.0 million for FY2025, 31.11% down from the prior year.
  • Share-based Compensation hit $1.6 million in Q4 2025 for Kezar Life Sciences, down from $2.1 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $6.6 million in Q3 2023 to a low of $1.6 million in Q4 2025.
  • Historically, Share-based Compensation has averaged $3.1 million across 5 years, with a median of $3.1 million in 2022.
  • Biggest five-year swings in Share-based Compensation: soared 105.99% in 2022 and later crashed 51.99% in 2024.
  • Year by year, Share-based Compensation stood at $1.9 million in 2021, then skyrocketed by 105.99% to $3.8 million in 2022, then dropped by 15.64% to $3.2 million in 2023, then rose by 2.7% to $3.3 million in 2024, then crashed by 50.8% to $1.6 million in 2025.
  • Business Quant data shows Share-based Compensation for KZR at $1.6 million in Q4 2025, $2.1 million in Q3 2025, and $2.4 million in Q2 2025.